Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture

Effective control of COVID-19 requires antivirals directed against SARS-CoV-2. We assessed 10 hepatitis C virus (HCV) protease-inhibitor drugs as potential SARS-CoV-2 antivirals. There is a striking structural similarity of the substrate binding clefts of SARS-CoV-2 main protease (M-pro) and HCV NS3/4A protease. Virtual docking experiments show that these HCV drugs can potentially bind into the M-pro substrate-binding cleft. We show that seven HCV drugs inhibit both SARS-CoV-2 M-pro protease activity and SARS-CoV-2 virus replication in Vero and/or human cells. However, their M-pro inhibiting activities did not correlate with their antiviral activities. This conundrum is resolved by demonstrating that four HCV protease inhibitor drugs, simeprevir, vaniprevir, paritaprevir, and grazoprevir inhibit the SARS CoV-2 papain-like protease (PLpro). HCV drugs that inhibit PLpro synergize with the viral polymerase inhibitor remdesivir to inhibit virus replication, increasing remdesivir's antiviral activity as much as 10-fold, while those that only inhibit M-pro do not synergize with remdesivir.

Automated summary

Some hepatitis C virus protease inhibitor drugs can inhibit SARS-CoV-2 virus replication and enhance the antiviral activity of other drugs, but not all drugs have this effect.